Technical Analysis for ABBV - AbbVie Inc.
|Grade||Last Price||% Change||Price Change|
ABBV closed up 0.46 percent on Thursday, October 19, 2017, on 1.39 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Oct 27
|See historical ABBV trend table...|
|Date||Alert Name||Type||% Chg|
|Oct 19||New 52 Week High||Other||0.00%|
|Oct 19||New 52 Week Closing High||Bullish||0.00%|
|Oct 19||Upper Bollinger Band Walk||Other||0.00%|
|Oct 18||New 52 Week High||Other||0.46%|
|Oct 18||Wide Range Bar||Range Expansion||0.46%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ABBV news...
|52 Week High||96.44|
|52 Week Low||53.6576|
|200-Day Moving Average||69.3869|
|50-Day Moving Average||82.1722|
|20-Day Moving Average||89.8056|
|10-Day Moving Average||92.0113|
|Average True Range||1.8338|
|Chandelier Exit (Long, 3 ATRs )||91.1186|
|Chandelier Exit (Short, 3 ATRs )||88.1151|
|Upper Bollinger Band||95.8814|
|Lower Bollinger Band||83.7298|
|Percent B (%b)||1.05|
|MACD Signal Line||3.0279|
|Market Cap||153.8 Billion|
|Num Shares||1.59 Billion|
|Price-to-Earnings (P/E) Ratio||23.71|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||99.65|
|Resistance 3 (R3)||99.34||97.98||99.12|
|Resistance 2 (R2)||97.98||97.17||98.13||98.94|
|Resistance 1 (R1)||97.23||96.68||97.61||97.54||98.77|
|Support 1 (S1)||95.12||95.06||95.50||95.43||94.19|
|Support 2 (S2)||93.76||94.57||93.91||94.02|
|Support 3 (S3)||93.01||93.76||93.84|
|Support 4 (S4)||93.32|